Is Alterity Therapeutics (ATHE) stock Halal?

Alterity Therapeutics is a biotechnology company focused on developing therapies for neurodegenerative diseases. Based in Australia, the company dedicates its research and development efforts to addressing conditions such as Parkinson's disease and other disorders associated with the degradation of brain function. Alterity Therapeutics is recognized for its pioneering work in targeting intracellular biological pathways that contribute to the progression of these diseases. For Muslim investors, though, the most pressing question is simpler: is Alterity Therapeutics a Halal investment?

Is Alterity Therapeutics Shariah compliant?

No. In the October 2026 screening Alterity Therapeutics (ATHE) does not pass AAOIFI screening: it fails the non-permissible income screen. Technology companies rarely fail AAOIFI screening on what they sell. Software, hardware and digital services are permissible business activities, so for a company like Alterity Therapeutics the Shariah question moves to the balance sheet: how much of its market value sits in interest bearing debt, how much of its cash earns Riba in conventional deposits, and whether incidental income from impermissible sources creeps past 5% of revenue. These are exactly the ratios AAOIFI Shariah Standard No. 21 polices, and they move every month with the share price.

Does Alterity Therapeutics pass the business activity test?

The activity screen is only part of the picture this month: Alterity Therapeutics currently fails the non-permissible income screen, so the overall verdict is not compliant regardless of the business itself. The watch item for technology names is incidental: cash returns and platform content can carry impermissible elements, which AAOIFI tolerates only below the thresholds.

Is Alterity Therapeutics' income Halal?

No. Alterity Therapeutics' income from impermissible sources currently exceeds AAOIFI's 5% revenue ceiling, which makes the stock non-compliant on this screen regardless of the others. The screen is reassessed monthly, so the status can change when new financial statements arrive.

Does Alterity Therapeutics meet AAOIFI's debt and investment ratio requirements?

Yes. Both caps hold this month: interest bearing investments and interest bearing debt each stay below 30% of market capitalisation, measured against a market capitalisation of $66.5M (market data as of 1 October 2026). Because the caps move with the share price, our Shariah Supervisory Board has ATHE re-screened every month, and the result above always shows the latest verdict.

Why do other halal screeners show a different verdict for Alterity Therapeutics?

Screeners can disagree without either being wrong. AAOIFI Shariah Standard No. 21, which Tabadulat applies, measures interest bearing debt and investments against market capitalisation with a 30% ceiling. MSCI and FTSE measure them against total assets with a 33% ceiling, and S&P and Dow Jones Islamic use a multi year average of market capitalisation. Data dates differ too, because each provider reads filings and prices on its own schedule. The same company can therefore pass one standard and fail another in the same month. Tabadulat publishes one answer, the AAOIFI result as of October 2026, and re-screens it every month.

Tabadulat is an ADGM regulated brokerage whose license covers Shari'a Compliant Regulated Activities, as the FSRA permission names them. New to the terminology? Gharar and Maysir, Sukuk, Zakat and purification are all explained in plain English.

New to the screening method? Read Why a Halal Stock Screener Matters for Halal Investing